Early detection of cancer allows applying an effective treatment and saving a life of patient.

It was shown that the beginning of cancer is accomplished by an aberrant methylation of some genes and these genes become silent, they are switched off. Determination of silent  genes allows to detect cancer at the early stages when still there are no clinical indications of disease.

Recently developed epigenetic methods of cancer diagnostic allow to detect the disease at early stages. However, these epigenetic tests are based on method of bisulfite conversion, which is quite complicated and often results in false-positive/negative data. That is why such tests are not widely used.

Novel GLAD-PCR method for detection of methyladed DNA may replace bisulfite conversion. It is simple, easy, very sensitive and not expensive.

Based on new method, EpiGene LLC, develops new epigenetic tests suitable for screening and early diagnostics of lung, breast, stomach and colorectal cancer.


Medica 2019

Epigene LLC recently has taken part in Medica tradefair 2019.